| Fiscal Year End | Company Status | Exempt Flag |
| December 31 | Delist | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 18/May/2007 | 25/Nov/2014 | Canada | | |
|
|
| Exchange Filing Office |
| Location |
| (not available) |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Research and Development in the Physical, Engineering and Life Sciences
| News Release June 11, 2014-Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax? platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.
|
|
| *Capital Pool Company
| (not available)
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *IMV | *Immunovaccine Inc. | TSX Venture | DELIST |
| *RHI.P | *Rhino Resources Inc. | TSX Venture | DELIST |
|
|
| Name History | From | To |
| *Immunovaccine Inc. | 5/Oct/2009 | 25/Nov/2014 |
| *Rhino Resources Inc. | 19/Jun/2007 | 4/Oct/2009 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Fall 2014 CFR | Not Received |
|
|
|
|
|
